Structure via PubChem · Public domain (PubChem)
lixivaptan
Sign in to saveAlso known as VPA-985, VPA985, WAY-VPA-985
Lixivaptan (VPA-985) is an orally-active, non-peptide, selective vasopressin V2 receptor antagonist being developed as an investigational drug by Palladio Biosciences, Inc. (Palladio), a subsidiary of Centessa Pharmaceuticals plc. , lixivaptan is in phase III clinical development for the treatment of autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to lixivaptan for the treatment of ADPKD.
Chemical data
- Formula
- C27H21ClFN3O2
- Molecular weight
- 473.9 g/mol
- IUPAC name
- N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide
- SMILES
- CC1=C(C=C(C=C1)F)C(=O)NC2=CC(=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53)Cl
- InChIKey
- PPHTXRNHTVLQED-UHFFFAOYSA-N
- XLogP
- 4.8
- Polar surface area
- 54.3 Ų
- H-bond donors
- 1
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- congestive heart failure, Hyponatremia, Autosomal dominant polycystic kidney disease, Polycystic Kidney Disease
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 473.130633
Show 3 more facts
- chemical formula
- C₂₇H₂₁ClFN₃O₂
- canonical SMILES
- CC1=C(C=C(C=C1)F)C(=O)NC2=CC(=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53)Cl
- Commons category
- Lixivaptan
Sources (2)
via Wikidata · CC0
~7 min read
Encyclopedic overview
12 sectionsContents
- Mechanism of action
- Hyponatremia
- ADPKD
- Research
- V<sub>2</sub> receptor antagonists in ADPKD
- Clinical studies
- Hyponatremia
- ADPKD
- The ACTION study
- The ALERT study
- DILIsym simulations
- References
Lixivaptan (VPA-985) is an orally-active, non-peptide, selective vasopressin V2 receptor antagonist being developed as an investigational drug by Palladio Biosciences, Inc. (Palladio), a subsidiary of Centessa Pharmaceuticals plc. , lixivaptan is in phase III clinical development for the treatment of autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to lixivaptan for the treatment of ADPKD.
==Mechanism of action== Lixivaptan is a potent, non-peptide, selective vasopressin receptor antagonist. It is a member of the vaptan class of drugs.
Excerpted from Wikipedia’s “lixivaptan” article, available under the CC BY-SA 4.0 licence.